GNLX · Genelux Corp
United States · RS rating 17 · As of 2026-10-14
| Price | 2.32 USD |
|---|---|
| 1-day change | -7.9% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 33 / 21 / 12 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 21 / 17 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -5.0% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +71.8% |
| Market cap (USD) | $112.9M |